John Markels - 01 Aug 2023 Form 4 Insider Report for Arcturus Therapeutics Holdings Inc. (ARCT)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ARCT	Stock option (right to buy)	Award	$0	+11,869		$0.000000	11,869	01 Aug 2023	Common Stock	11,869	$34.92	Direct	F1
transaction	ARCT	Deferred Stock Units	Award	$0	+3,131		$0.000000	3,131	01 Aug 2023	Common Stock	3,131		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	Shares underlying the option vest monthly over a one year period from the date of grant; provided however, that the remaining unvested balance will vest and become fully exercisable at the Issuer's 2024 annual meeting of stockholders. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.
F2	Each deferred stock unit is economically equivalent to one share of the Issuer's common stock.
F3	Shares underlying the deferred stock units shall vest at the Issuer's 2024 annual meeting of stockholders. The shares underlying the deferred stock units will be issued on (or as soon as reasonably practicable following) the earlier of the Reporting Person's separation from service or a change in ownership of the Issuer or a substantial portion of its assets or a change in effective control of the Issuer within the meaning of regulations issued under Section 409A of the Internal Revenue Code. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.